Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350614 | 0.93 | CA2 (0.53) | CA2ALDH1A1SLC6A4MAOA | |
| SCHEMBL1403717 | 0.91 | ALDH1A1 (0.53) | CA2ALDH1A1HPGDHSD17B10SLC6A4 | |
| SCHEMBL23582819 | 0.82 | CA2 (0.67) | CA2ALDH1A1HPGDHSD17B10CAMK2A | |
| SCHEMBL2651928 | 0.77 | ALDH1A1 (0.55) | CA2ALDH1A1HPGDHSD17B10MAOA | |
| SCHEMBL11004878 | 0.77 | SLC6A4 (0.47) | ALDH1A1HPGDHSD17B10SLC6A4MAOA | |
| SCHEMBL11690462 | 0.77 | CA2 (0.52) | CA2ALDH1A1HPGDHSD17B10CAMK2A | |
| SCHEMBL11479383 | 0.77 | AKR1C3 (0.57) | CA2ALDH1A1HPGDHSD17B10CAMK2A | |
| SCHEMBL11007196 | 0.75 | SLC6A4 (0.46) | ALDH1A1HPGDHSD17B10SLC6A4MAOA | |
| SCHEMBL3490695 | 0.74 | CA2 (0.57) | CA2SLC6A4MAOA | |
| SCHEMBL670933 | 0.74 | PKM (0.51) | CA2ALDH1A1HPGDHSD17B10CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | CA2 852/4885ALDH1A1 1730/4885HPGD 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.